公开(公告)号：US20240366759A1

公开(公告)日：2024-11-07

申请号：US18572990

申请日：2022-06-21

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Benjamin YOUNGBLOOD ,  Giedre KRENCIUTE ,  Stephen GOTTSCHALK ,  Brooke PRINZING ,  Caitlin ZEBLEY

IPC: A61K39/00 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and IL10 signaling pathway is enhanced. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

公开(公告)号：US20240216427A1

公开(公告)日：2024-07-04

申请号：US18270675

申请日：2021-12-29

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stephen GOTTSCHALK ,  Jessica WAGNER ,  Elizabeth WICKMAN ,  Timothy Isham SHAW ,  Jinghui ZHANG

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/18

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/18 ,  A61K2239/13 ,  A61K2239/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

Abstract: The application provides chimeric antigen receptors (CARs) that target splice variants of the extracellular matrix proteins tenascin C (TNC) and procollagen 11A1 (Col11A1), and their uses in tumor immunotherapy. The application also provides polynucleotides and vectors that encode the chimeric antigen receptors, as well as host cells comprising the chimeric antigen receptors. The application also provides methods for preparing host cells comprising the chimeric antigen receptors and methods for treating patients using the modified host cells.

公开(公告)号：US20230340040A1

公开(公告)日：2023-10-26

申请号：US17918644

申请日：2021-04-14

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stephen GOTTSCHALK ,  Brooke PRINZING

IPC: C07K14/47 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K14/4702 ,  A61P35/00 ,  C12N15/63 ,  C07K2319/03

Abstract: The present disclosure provides chimeric MyD88 receptors. Also provided are polynucleotides encoding the chimeric MyD88 receptors, vectors comprising the polynucleotides encoding the chimeric MyD88 receptors, and cell compositions comprising the chimeric MyD88 receptors, polynucleotides and/or vectors. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.

公开(公告)号：US20250059591A1

公开(公告)日：2025-02-20

申请号：US18707999

申请日：2022-11-07

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Paul G. THOMAS ,  Stephen GOTTSCHALK ,  Taylor WILSON ,  Jeremy Chase CRAWFORD ,  Hyunjin KIM

IPC: C12Q1/6809 ,  A61K35/17 ,  C12N5/0783 ,  C12Q1/6869

Abstract: The present disclosure relates generally to methods for generating a pre-effector gene signature for determining the C cytotoxic effector potential of a preparation of chimeric antigen receptor (CAR) T cells comprising measuring single-cell gene expression data and endogenous T cell receptor (TCR) sequencing data of the preparation of CAR T cells. The present invention relates also to methods for determining the cytotoxic effector potential of a preparation of CAR T cells or a subset of CAR T cells therefrom as well as methods for treating a cancer in a subject in need thereof by administering a preparation of CAR T cells determined to have a cytotoxic effector potential.

公开(公告)号：US20230340067A1

公开(公告)日：2023-10-26

申请号：US18003093

申请日：2021-06-25

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stephen GOTTSCHALK ,  Giedre KRENCIUTE ,  Zelda ODE

IPC: C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C12N5/0783 ,  C12N15/11 ,  C12N9/22 ,  C12N15/90

CPC classification number: C07K14/70521 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C12N5/0636 ,  C12N15/11 ,  C12N9/22 ,  C12N15/907 ,  C07K2319/03 ,  C12N2310/20 ,  C12N2800/80

Abstract: The present invention provides methods of genetically modifying an immune cell such that the immune cell expresses a transgene in an activation dependent manner. The application also provides genetically modified immune cells prepared using such methods, and the uses of the genetically modified immune cells in immunotherapy (e.g., adoptive cell therapy) for treatment of a disease such as cancer, autoimmune disease or infectious disease.

公开(公告)号：US20250064933A1

公开(公告)日：2025-02-27

申请号：US18724820

申请日：2022-12-29

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stephen GOTTSCHALK ,  Peter CHOCKLEY

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/725 ,  C07K16/30

Abstract: The present application provides chimeric antigen receptors (CARs) comprising an anchoring domain, such as a PDZ binding motif, which binds to a cell polarity protein. Also provided are poly nucleotides encoding the CARs, vectors, and cell compositions comprising the same. Pharmaceutical compositions comprising the polypeptides, polynucleotides, vectors, or cells of the present disclosure, and their uses in treating a disease in a subject are also provided.

公开(公告)号：US20230312671A1

公开(公告)日：2023-10-05

申请号：US17919728

申请日：2021-04-23

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Mireya Paulina VELASQUEZ ,  Stephen GOTTSCHALK ,  Nikhil HEBBAR ,  Rebecca EPPERLY ,  Abishek VAIDYA

IPC: C07K14/725 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K14/7051 ,  A61P35/00 ,  C12N15/63 ,  C07K2319/02 ,  C07K2319/03

Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising at least one glucose-regulated-protein 78 (GRP78)-binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the host cells and methods for treating a tumor using the pharmaceutical compositions.

公开(公告)号：US20230030680A1

公开(公告)日：2023-02-02

申请号：US17791181

申请日：2021-01-06

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stephen GOTTSCHALK ,  Laurens SAND ,  Shannon LANGE

IPC: C07K14/715 ,  A61K35/17

Abstract: The present invention provides chimeric cytokine receptors, particularly chimeric cytokine receptors that canbe activated in tumor microenvironment, and their uses in tumor immunotherapy (e.g., adoptive cell therapy). The present invention further provides methods of genetically modifying therapeutic cells resulting in an enhanced immune response against a target antigen. The application further provides therapeutic cells that express said chimeric cytokine receptors and methods for treating patients using the modified therapeutic cells.

公开(公告)号：US20220226379A1

公开(公告)日：2022-07-21

申请号：US17602524

申请日：2020-04-08

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

Inventor： Stephen GOTTSCHALK ,  Giedre KRENCIUTE ,  Christopher PETERSEN ,  Benjamin YOUNGBLOOD

IPC: A61K35/17 ,  A61P35/02 ,  A61K35/545 ,  C12N9/10

Abstract: The application provides modified immune effector cells wherein the DNA (cytosine-5)-methyltransferase 3A (DNMT3A)-mediated de novo DNA methylation of the cell genome is inhibited, and STAT5 signaling pathway is activated. The application also provides related pharmaceutical compositions and the methods for generating such modified immune effector cells. The application further provides uses of such modified immune effector cells for treating diseases such as cancers, infectious diseases and autoimmune diseases.

公开(公告)号：US20230174653A1

公开(公告)日：2023-06-08

申请号：US17917198

申请日：2021-04-06

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Stephen GOTTSCHALK ,  Christopher DERENZO ,  Phuong NGUYEN

IPC: C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  A61P35/00 ,  A61K35/17

CPC classification number: C07K16/2827 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

Abstract: The present invention provides a chimeric antigen receptor (CAR) comprising an extracellular target-binding domain comprising a B7-H3 binding moiety. The present invention further provides polynucleotides and recombinant vectors encoding such CARs. The present invention further provides isolated host cells and methods for preparing isolated host cells expressing the CARs. The present invention further provides pharmaceutical compositions comprising the isolated host cells and methods for treating a tumor using the pharmaceutical compositions.